Causeway Capital Management LLC Sells 378,520 Shares of Pfizer Inc. (NYSE:PFE)

Causeway Capital Management LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 17.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,832,790 shares of the biopharmaceutical company’s stock after selling 378,520 shares during the quarter. Pfizer accounts for about 1.1% of Causeway Capital Management LLC’s investment portfolio, making the stock its 26th largest position. Causeway Capital Management LLC’s holdings in Pfizer were worth $48,624,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer during the 4th quarter valued at about $31,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter valued at approximately $33,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 1.4 %

Shares of Pfizer stock opened at $21.89 on Monday. The firm has a market capitalization of $124.14 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm’s 50 day simple moving average is $25.25 and its two-hundred day simple moving average is $26.38. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the firm posted $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.